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S U M M A R Y
Some viruses, including certain members of the enterovirus genus, have been reported to cause
nephrotic syndrome. However, no case of coxsackievirus A16 (CVA16)-related nephrotic syndrome has
been reported so far. We describe a case of CVA16-related hand, foot and mouth disease presenting with
nephrotic syndrome in a 3-year-old boy. This is the ﬁrst report of CVA16-related nephrotic syndrome.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Coxsackievirus A16 (CVA16), a member of the Enterovirus A
species, is a common causative pathogen of hand, foot and mouth
disease (HFMD). Most CVA16-related HFMD cases are mild, with
rashes, fever, or an acute respiratory infection; only a few present
complications of the central nervous system. Many pathogens have
been reported to cause nephrotic syndrome or glomerulonephritis.
Some members of the Enterovirus B species have also been reported  to
cause glomerulonephritis,1 however to our knowledge, no coxsack-
ievirus A16 (CVA16)-associated nephrotic syndrome or glomerulone-
phritis has been reported so far. We describe a case of CVA16-related
HFMD presenting with nephrotic syndrome in a 3-year-old boy.
1.1. Case report
A previously healthy 3-year-old Cantonese boy was hospital-
ized for generalized rashes, eyelid edema, and oliguria. Three days
before admission, a maculopapular rash with blisters in the center
had appeared on his hip and this had then spread to the palms of
his hands and feet over the following 2 days. Swelling of the eyelids
and oliguria began to appear a day before admission. Before* Corresponding author. Tel.: +86 20 62783662.
E-mail address: chexiaoyan@126.com (X.-Y. Che).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).admission the boy had presented no fever, but had occasionally
emitted a single cough. His past medical history showed no record
of kidney disease.
A physical examination done on admission revealed hyperten-
sion (109/63 mmHg) and a normal temperature, pulse rate, and
breathing rate. Moderate edema was noted in the eyelids, rather
than in other parts of the body. Conspicuous dark red maculo-
papular rashes on hip, palms and feet, vesicles in mouth cavity
membrane were observed. Rough breathing sounds were heard on
auscultation. No other abnormality was found during the
admission physical examination.
Urinalysis revealed moderate hematuria (red blood cell count
(RBC) 35  106/l), mild leukocyturia (white blood cell count (WBC)
12  106/l), and severe proteinuria (proteinuria 4+). The speciﬁc
gravity of the urine was within the normal range. Severe
hypoalbuminemia (11.3 g/l) and mild hyperglobulinema (37.0 g/
l) were found in the admission tests. The following serum lipid
values suggested hyperlipidemia: total cholesterol 7.48 mmol/l,
total triglyceride 2.76 mmol/l, high density lipoprotein choles-
terol (HDL-C) 1.65 mmol/l, low density lipoprotein cholesterol
(LDL-C) 5.38 mmol/l, lipoprotein a (Lpa) 2407 mg/l, apolipoproteins
A1 (ApoA1) 2.11 g/l, apolipoproteins B (ApoB) 1.93 g/l. Admission
tests also showed slight hypocalcemia (1.98 mmol/l), mild
azotemia (8.0 mmol/l), and an elevated erythrocyte sedimenta-
tion rate (80 mm/h). No other abnormality was found for the
admission tests.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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furosemide on the day of admission due to oliguria and edema. His
urine output responded to treatment with a jump from 353 ml/
24 h on the day of admission to approximately 1100 ml/24 h on the
other days, except for 770 ml/24 h on day 16 of hospitalization. The
edema grew worse on the day following admission, with the
appearance of facial edema and pitting edema in the lower
extremities; the edema then resolved gradually and disappeared
on day 7 of hospitalization. However, the edema reappeared on day
16 of hospitalization and eventually disappeared completely on
day 21 of hospitalization. The highest blood pressure observed
during the hospitalization was 118/78 mmHg. During his 27-day
hospitalization, the patient was also treated with bed rest, human
immunoglobulin, acyclovir, methylprednisolone, atomization in-
halation, and supportive treatments. Urinalysis showed a trend of
gradually declining protein, WBC, and RBC in the urine, and these
eventually reverted to normality on day 21 of hospitalization. The
total content of urine protein was 2801 mg/24 h on day 4 of
hospitalization. The boy was eventually discharged without
hypertension, edema, or cough. On the day of discharge, all serum
biochemical tests were normal except for slightly low levels of
albumin (33.3 g/l) and total protein (52.4 g/l). The total content of
24 h urine protein was normal at 35.2 mg/24 h on the day before
discharge. During the 2-year follow-up he showed no recurrence of
edema, hypoproteinemia, hyperlipidemia, or hypertension, how-
ever there was a relapse of slight proteinuria (+ to ++) and
microscopic hematuria occurred now and then.
Other relevant tests and examinations during his hospitaliza-
tion were the following: real-time reverse transcription PCR (RT-
PCR) test results from a stool sample were positive for pan-
enterovirus and CVA16, and negative for enterovirus 71. Genotyp-
ing of sequenced viral protein 1 (VP1) further conﬁrmed the CVA16
infection. PCR was negative for both Epstein–Barr virus (EBV) and
cytomegalovirus (CMV) in blood. Testing for hepatitis B virus
(HBV) showed 0 IU/ml level of hepatitis B surface antigen (HBsAg)
(0 IU/ml–0.05 IU/ml) and 324.03 mIU/ml level of anti-HBsAg
antibody (HBsAb) (0 mIU/ml–10 mIU/ml). Both antinuclear anti-
body and anti-double-stranded DNA antibodies were negative.
Serum testing also showed C3 and C4 complement, titers of
rheumatoid factor, anti-streptolysin O antinuclear antibody (ANA),
and anti-DNA antibody to be within the normal ranges.
2. Discussion
We have presented a case of CVA16-related nephrotic
syndrome secondary to HFMD. The positivity for CVA16 and
typical HFMD rash distribution suggested CVA16-related HFMD.
The manifestations of hematuria, leukocyturia, edema, oliguria,
massive proteinuria (2801 mg/24 h), hypoalbuminemia (11.3 g/l),
and hyperlipidemia (cholesterol 9.05 mmol/l, triglycerides
2.76 mmol/l) in this 3-year-old child meet the diagnostic indices
of nephrotic syndrome. Combined with the presentations of
hypertension, azotemia, and microscopic hematuria, the case is
consistent with a nephritis type of nephrotic syndrome.
Since the response to treatment was good, with obvious
improvements in clinical and laboratory manifestations, a renal
biopsy was not performed to acquire the pathology type and to
provide pathological evidence ascertaining CVA16 as the incon-
trovertible pathogen causing the nephrotic syndrome in this case.
Establishing CVA16 as the causative pathogen of nephrotic
syndrome in this case was based on the following evidence:
CVA16 positivity, negative renal disease history, occurrence of
oliguria lagging 2 days behind eruptions, normal levels ofrheumatic factor, anti-streptolysin O, and antinuclear antibody,
and negativity for antinuclear antibody, anti-double-stranded DNA
antibody, HBV, CMV, and EBV. Due to the presence of CVA16 and
the ruling out of possible pathogenic factors for glomerulonephri-
tis in a Cantonese patient (autoimmune diseases, Streptococcus,
HBV, and EBV), the CVA16 infection was deemed to be the most
likely pathogenic factor for nephrotic syndrome in this case.
Members of coxsackievirus B have been reported to be
causative pathogens of glomerulonephritis.1 A pathological study
has shown that coxsackieviruses B1–6 can produce cytopathic
effects in human proximal tubular epithelial cells and podocytes.2
Coxsackievirus and adenovirus receptor (CAR), a widely expressed
transmembrane protein that could serve as a receptor for
coxsackievirus B, is expressed on the cell membrane from the
kidney.3 Similar to coxsackievirus B, CVA16 also has a ubiquitously
expressed receptor in human tissue, namely scavenger receptor
class B member 2 (SCARB2).4 The ubiquitously expressed SCARB2
means that CVA16 also has a chance of binding to cells of the
kidney, causing kidney diseases. African green monkey kidney cells
(Vero) are used widely for culturing and isolating enteroviruses,
including CVA16. As the evidence above suggests that CVA16 can
cause a cytopathic effect by direct infection as does coxsackievirus
B, the pathophysiological mechanism by which the nephritis type
of nephrotic syndrome was caused in this case may be as follows:
the cytopathic and lytic effects caused by direct CVA16 infection
damaged the proximal tubular epithelial cells and molecular
barrier of the glomerular ﬁltration membrane and charge barrier,
leading to manifestations of proteinuria, hematuria, leukocyturia,
and hypoalbuminemia in the acute phase, while the relapse of
slight proteinuria and microscopic hematuria was likely caused by
precipitated immune complex-related glomerular injury. Although
the incidence of CVA16 is higher than that of any member of
coxsackievirus B in many countries, to our knowledge, no CVA16-
related glomerulonephritis or nephrotic syndrome has been
reported so far. This may be due to factors including the viral
load in blood, density distribution of receptors in other organs,
complex interactions between immunity and virus, and reproduc-
tion capacity in cells of the glomerulus. In fact, kidney disease
caused by enterovirus is not unusual, and a study on 10 patients
with IgA nephropathy detected enterovirus in three out of
10 biopsies.5 To our knowledge, this is the ﬁrst case report of
glomerulonephritis caused by CVA16.
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